Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
14 p, 1.4 MB Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer : a pilot clinical trial / Quintela-Fandino, Miguel (Hospital Universitario Quiron. Medical Oncology Department) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Morales, Serafin (Hospital Arnau de Vilanova (València)) ; Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ; Colomer, Ramon (Universidad Autónoma de Madrid. Facultad de Medicina) ; Apala, Juan V. (Hospital Universitario de Fuenlabrada ( Madrid)) ; Blanco, Raquel (Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology) ; Muñoz, Manuel (Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center) ; Caleiras, Eduardo (Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Iranzo, Vega (Universitat de València. Departament de Medicina) ; Martínez López, Mario (Hospital Universitario 12 de Octubre (Madrid)) ; Dominguez, Orlando (Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Hornedo, Javier (Hospital Universitario Quiron. Medical Oncology Department) ; Gonzalez-Cortijo, Lucia (Hospital Universitario Quiron. Medical Oncology Department) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Gasol Cudos, Ariadna (Hospital Arnau de Vilanova (València)) ; Malon, Diego (Hospital Universitario de Fuenlabrada ( Madrid)) ; Lopez-Alonso, Antonio (Spanish National Cancer Research Center) ; Moreno-Ortíz, María C. (Centro Nacional de Biotecnología/CSIC) ; Mouron, Silvana (Spanish National Cancer Research Center) ; Mañes, Santos (Centro Nacional de Biotecnología/CSIC) ; Universitat Autònoma de Barcelona
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. [...]
2020 - 10.1186/s13058-020-01362-y
Breast cancer research, Vol. 22 (november 2020)  

Vegeu també: autors amb noms similars
1 Morales, S
1 Morales, S.
1 Morales, Salomé
2 Morales, Sergio
2 Morales, Soledad
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.